Laboratory Monitoring for JAK Inhibitors and Key Takeaways

Video content above is prompted by the following:

• Given this patient’s clinical picture, what initial dosing would you recommend?
• What monitoring should be done before and during treatment with baricitinib? How does this differ from monitoring with ritlecitinib?
• What can this patient expect in terms of efficacy and safety with baricitinib?
• When would topical immunotherapy be considered for patients with severe alopecia areata? How do you decide between topical immunotherapy and JAK inhibitors for your patients?
• Based on our discussion today, what key insights or new perspectives could you share regarding treatment considerations for severe alopecia areata?
• What treatment gaps remain in alopecia areata management?
• What take-home messages or practice pearls do you have for clinicians treating patients with alopecia areata?